https://healthfirsteurope.eu/wp-content/uploads/2019/03/books-1845614.jpgtopic

AMR Patient Group

AS FROM JUNE 2022, YOU CAN FIND ALL THE INFORMATION AND NEWS ABOUT THE AMR PATIENT GROUP HERE: https://amrpatientgroup.eu/

The first European AMR Patient Group was officially launched on the 18th November 2020 to coincide with European Antibiotic Awareness Day 2020 and World Antimicrobial Awareness Week (18-24 November). The AMR Patient Group is an initiative by Health First Europe and is comprised of national patient associations from across Europe. The group aims to address the gap in awareness at the patient-level about the danger of antibiotic misuse and the lack of effective infection prevention measures. The AMR Patient Group will empower patients across Europe with the necessary knowledge about antimicrobial resistance so that everyone understands when it is appropriate to take antibiotics and how to take them responsibly.

The key objectives of the AMR Patient Group are:

  1. Raising patient awareness about AMR and HAIs to help reduce antibiotic misuse.
  2. Building a consistent patient voice across Europe to advocate for national policies to tackle AMR and HAIs.
  3. Broadening the AMR debate to include infection prevention and control measures.

What is AMR and why is it important?

Antimicrobial Resistance (AMR) is the ability of a microorganism (e.g., a bacterium, a virus, or a parasite) to resist the action of one or more antimicrobial agents or antibiotics. Levels of antibiotic consumption consistently correlate with levels of antibiotic resistance, i.e. the more an antibiotic is used, the more resistant the bacteria can become. As a result, antibiotics will not be able to treat infections any longer.

Antimicrobial resistance is one of the most serious threats to public health globally. It is responsible for an estimated 33,000 deaths per year in the EU and is estimated to cost the EU €1.5 billion annually in healthcare costs and productivity losses. Without effective antibiotics to prevent or treat infections, some routine surgical operations and cancer chemotherapies may become very high-risk procedures, or even become impossible due to the increased likelihood of resistant infections. Resistant bacteria can kill and can spread to others, creating huge risks for patients and problems for society at large.

Keeping antibiotics effective is everyone’s responsibility. Responsible use of antibiotics can help stop resistant bacteria from developing and help keep antibiotics effective for the use of future generations. On this basis, it is important for everyone to know when it is appropriate to take antibiotics and how to take them responsibly.

 

View the AMR Patient Group launch press release

AMR Patient Group launch 18.11.20 – English

AMR Patient Group launch 18.11.20 – Spanish

AMR Patient Group launch 18.11.20 – French

AMR Patient Group launch 18.11.20 – Portuguese

AMR Patient Group launch 18.11.20 – Italian

AMR Patient Group launch 18.11.20 – German

 

AMR Patient Group members

Our members to date include:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Learn more about AMR and other healthcare associated infections (HAI)

To learn more about the work Health First Europe is doing, you can view our dedicated AMR page here.

European Commission

European Centre for Disease Prevention and Control (ECDC)

European Parliament

World Health Organization (WHO)

OECD

Council of the European Union

 

More about AMR Patient Group

The AMR Patient Group contributes to the European Commission's Call for Evidence on Antimicrobial Resistance
2022

In February 2022, the European Commission launched a Call for Evidence for their upcoming Recommendation to Member States for greater action on Antimicrobial Resistance. Here is our contribution.

PRESS RELEASE: Launch of a new group of MEP Ambassadors of the AMR Patient Group
2022

HFE together with the members of the European Patient Group on Antimicrobial Resistance (AMR Patient Group) are delighted to announce the creation of a new group of Members of the European Parliament (MEP) who have agreed to become the new MEP Ambassadors of the AMR Patient Group.

A community-based survey of the general public’s knowledge, behaviour and awareness related to antimicrobial resistance
2021 || News

The European AMR Patient Group invites you to fill in the pan-European survey to assess the level of knowledge and awareness of antimicrobial resistance (AMR) and health-associated infections (HAIs) among 5 European countries, namely Italy, France, Germany, Spain and the UK.

EDITORIAL: European AMR Patient Group Scales up Education and Outreach on Antimicrobial Resistance
2021 || Editorial, News

Patient safety is an essential metric when it comes to building resilient public healthcare systems both at the European and global level. It is also indispensable in the provision of health care in all settings including hospitals and long-term care facilities.

2021 Declaration of the European Patient Group on Antimicrobial Resistance
2021

We, the members of the European Patient Group on Antimicrobial Resistance (AMR Patient Group), are truly committed to raising awareness about the real-world impact of antimicrobial resistance (AMR) and healthcare-associated infections (HAIs). Consequently, we we have prepared a Declaration to help reduce the inappropriate use of existing antibiotics, promote antimicrobial stewardship and infection prevention and control measures across Europe, and develop novel antibiotics where needed. 

First Workshop of the AMR Patient Group
2020

Health First Europe is organising the first workshop of the newly created AMR Patient Group which will take place on Wednesday 16 December 2020 from 10:00 to 12:30 CET via RingCentral.

PUBLICATION: Declaration and Infographic of the European Patient Group on Antimicrobial Resistance
2021

We, the members of the European Patient Group on Antimicrobial Resistance (AMR Patient Group), are truly committed to raising awareness about the real-world impact of antimicrobial resistance (AMR) and healthcare-associated infections (HAIs). Consequently, we we have prepared a Declaration to help reduce the inappropriate use of existing antibiotics, promote antimicrobial stewardship and infection prevention and control measures across Europe, and develop novel antibiotics where needed.